Nicorandil Could Improve Exercise in Heart Failure
A small trial shows patients with certain heart failure types may walk further with this treatment.
Updated on Oct. 30, 2026 in Heart Disease
Live Poll
Do you believe clinical study results significantly influence your personal approach to managing long-term health conditions?
A clinical trial found that oral nicorandil significantly improved exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF) and coronary microvascular dysfunction. The study provides new data for individuals navigating these heart conditions, though findings remain preliminary.
Why it matters
Managing HFpEF alongside microvascular dysfunction is challenging due to limited treatment options that directly improve heart blood flow. This finding suggests a potential pathway to better physical function for this patient population, pending further validation.
This randomized trial of 113 patients evaluated the impact of nicorandil on exercise capacity and blood flow over 24 months. While participants in the treatment arm saw improvements in coronary flow reserve compared to those on usual care, these early results require larger validation.
The details
Nicorandil acts as a potassium channel opener that also provides nitric oxide donor properties to help dilate blood vessels. In this trial, the medication was used to improve coronary microvascular function, which regulates how well blood flows to the heart muscle. By easing this restriction, the treatment helped participants achieve better performance on standard 6-minute walk tests compared to those receiving usual care alone.
Timeline
24 months of follow-up and assessment were completed for the study participants.
Health Landscape
Heart failure with preserved ejection fraction remains a complex condition where the heart pumps effectively but does not fill properly. This research explores an alternative pharmacological strategy to the current standard of care, which largely focuses on managing symptoms and comorbidities.
Patients experiencing reduced exercise capacity due to heart failure and microvascular dysfunction should discuss these findings with their cardiologist to determine if similar research applies to their care plan. This trial serves as a reminder to monitor and report changes in daily activity levels to your clinical team.
The takeaway
While this study suggests that nicorandil may improve exercise capacity, it remains a preliminary finding that needs further multicentre confirmation. Keep a log of your physical activity levels to share with your physician, as changes in endurance are essential markers to discuss during your checkups.
Further reading
For more information on current treatment strategies, visit our Heart Disease section.
Source note: This article includes information reported by European Medical Journal.
Live Poll
Do you believe clinical study results significantly influence your personal approach to managing long-term health conditions?
